Abstract:Recombinant tissue plasminogen activator (rPA) has been used as a thrombolytic agent.However,considerable improvements have been done to prolong its plasma half-life (tl/2) and reduce its side effects,such as intracranial hemorrhage.Based on these improvements,a mutant of rPA,mrPA,was designed by mutating its PAⅠ-1 binding site to extend its t1/2.Furthermore,a fusion protein conjugating mrPA with NR3 was designed,which was a rAcAp5 mutant with a platelet GPⅡb/Ⅲa-binding RGD motif,to enhance the ability of targeted-thrombus and thrombolysis.The synthesized DNA sequences coding the two proteins were amplified by PCR,cloned into pET30a to construct recombinant plasmids pET30a-mrPA and pET30a-mrPA-NR3,and transformed into E.coli BL21 (DE3).The two proteins were expressed in inclusion bodies induced by isopropyl ｀-D-1-thiogalactopyranoside.After purified to qualified purity using one-step Ni affinity chromatography,the denatured proteins were refolded by dialysis.Their thrombolytic effects in vitro and in vivo were evaluated.In vitro 3.5 and 7 μmol/L of mrPA significantly reduced thrombus weight;1.75,3.5 and 7 μmol/L of mrPA-NR3 also significantly reduced the thrombus weight,and mrPA-NR3 displayed stronger thrombolytic effects than mrPA at 7 μmol/L.In vivo both mrPA and mrPA-NR3 showed significantly thrombolytic effect at 60-240 μmol/kg in thrombolytic model of inferior vena cava.Importantly,mrPA-NR3 exhibited more potent thrombolytic effect than both mrPA and rhM-tPA (positive control) at 240 μmol/kg.In addition,these two novel proteins did not increase bleeding time while they exerted thrombolytic effect.In conclusion,we engineered two novel proteins and proved that fusion protein had better thrombolytic effect than non-fusion protein,and the results suggest that dual thrombolytic mechanism or thrombus-target potentiated the thrombolytic effect of rPA and alleviated hemorrhage side reaction.This study may shed light on the development of novel thrombolytic agents with targeted thrombolysis and reduced side effects.

Sustained Thromboprophylaxis Mediated by an RBC-targeted Pro-Urokinase Zymogen Activated at the Site of Clot Formation.

Targeting of A Mutant Plasminogen Activator to Circulating Red Blood Cells for Prophylactic Fibrinolysis

Prophylactic Thrombolysis by Thrombin-Activated Latent Prourokinase Targeted to PECAM-1 in the Pulmonary Vasculature

Endothelial Targeting of a Recombinant Construct Fusing a PECAM-1 Single-Chain Variable Antibody Fragment (scfv) with Prourokinase Facilitates Prophylactic Thrombolysis in the Pulmonary Vasculature

Packaging of supplemented urokinase into alpha-granules of in vitro -grown megakaryocytes for targeted nascent clot lysis

Delivery Of Anti-Platelet-Endothelial Cell Adhesion Molecule Single-Chain Variable Fragment-Urokinase Fusion Protein To The Cerebral Vasculature Lyses Arterial Clots And Attenuates Postischemic Brain Edema

Cerebrovascular Thromboprophylaxis in Mice by Erythrocyte-Coupled Tissue-Type Plasminogen Activator

Direct delivery of plasmin using clot-anchoring thrombin-responsive nanoparticles for targeted fibrinolytic therapy

Engineered Nanoplatelets for Targeted Delivery of Plasminogen Activators to Reverse Thrombus in Multiple Mouse Thrombosis Models

Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion

The spatial dynamics of fibrin clot dissolution catalyzed by erythrocyte-bound vs. free fibrinolytics

Engineered platelets-based drug delivery platform for targeted thrombolysis

Thrombin Stimulation of Platelets Induces Plasminogen Activation Mediated by Endogenous Urokinase-Type Plasminogen Activator

A Recombinant Antibody-Targeted Plasminogen Activator with High Affinity for Activated Platelets Increases Thrombolytic Potency in Vitro and in Vivo.

Targeting Recombinant Thrombomodulin Fusion Protein to Red Blood Cells Provides Multifaceted Thromboprophylaxis

A Specific Plasminogen Activator Inhibitor-1 Antagonist Derived from Inactivated Urokinase

Construction and Expression of A Recombinant Antibody-Targeted Plasminogen Activator Composed of A Humanized Monoclonal Antibody Against Activated Human Platelets and A Single-Chain Urokinase

Thrombus Targeted Delivery of Urokinase and Ticagrelor for Thrombosis-related Diseases Treatment

Erythrocyte-Inspired Discoidal Polymeric Nanoconstructs Carrying Tissue Plasminogen Activator for the Enhanced Lysis of Blood Clots

RGD Modified Protein-Polymer Conjugates for Ph-Triggered Targeted Thrombolysis

Design, Preparation and Activity Evaluation of Novel Recombinant Thrombolytic Proteins